Laboratory Monitoring for Eliquis (Apixaban)
Eliquis does not require routine laboratory monitoring for anticoagulation effect. 1
Essential Baseline and Periodic Monitoring
While therapeutic drug monitoring is not needed, certain laboratory parameters should be assessed:
Renal Function Monitoring
- Creatinine clearance (CrCl) using Cockcroft-Gault equation is the most important lab to monitor 2
- Check at baseline and periodically, especially in patients with:
- Age ≥80 years
- Body weight ≤60 kg
- Baseline serum creatinine ≥1.5 mg/dL
- More frequent monitoring needed in patients with declining renal function, as apixaban is 27% renally cleared 2
Liver Function Tests
- Baseline transaminases (ALT, AST), alkaline phosphatase, and bilirubin 1
- Periodic monitoring if clinically indicated
- Note: Transaminase elevations occurred in 0.8% of patients in clinical trials 1
Complete Blood Count
- Baseline hemoglobin/hematocrit to detect anemia 1
- Monitor if bleeding suspected (hemoglobin decrease ≥2 g/dL is a marker of major bleeding) 1
When Apixaban Levels May Be Clinically Useful
Standard coagulation tests (PT, aPTT, INR) are NOT suitable for monitoring apixaban - they lack sensitivity and show high variability 1, 3, 4
Specific Clinical Scenarios Requiring Level Assessment:
- Emergency surgery or urgent procedures - to determine if clinically significant drug levels (>50-75 ng/mL) are present 5, 6
- Life-threatening bleeding - to guide reversal decisions 5
- Suspected overdose or toxicity 7
- Severe renal impairment (CrCl 15-29 mL/min) - apixaban levels may be prolonged 7
- Extremes of body weight 7
- Medication adherence assessment 7
Appropriate Assays for Apixaban Quantification:
If measurement is needed, use anti-Factor Xa chromogenic assay with apixaban-specific calibrators and controls 3, 8, 9
- Linear correlation with drug concentrations from 50-500 ng/mL 3
- Inter-laboratory precision <11% and accuracy <12% 3
- Expected trough levels: 76-104.5 ng/mL (varies by dose) 9
- Expected peak levels: 151-202 ng/mL (varies by dose) 9
Critical Pitfalls to Avoid
- Do not use PT/INR or aPTT to assess apixaban levels - these tests are insensitive and unreliable 1, 3, 4
- Do not delay emergency treatment waiting for drug levels - in life-threatening bleeding, initiate reversal immediately 5
- Do not assume normal PT/aPTT means no apixaban present - clinically significant levels can exist with normal routine coagulation tests 4
- Calculate CrCl using Cockcroft-Gault, not eGFR - this is what dosing recommendations are based on 2